F
Frédéric Rivière
Publications - 49
Citations - 912
Frédéric Rivière is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 42 publications receiving 663 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
Journal ArticleDOI
Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor?
TL;DR: The case of a 71-yr-old female smoker suffering from COPD who had not received inhaled or oral corticosteroid therapy, and who had suffered from bronchiectasis after pulmonary tuberculosis 60 yrs previously is reported.
Journal ArticleDOI
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jean-Marc Naccache,Stéphane Jouneau,Morgane Didier,Raphael Borie,Marine Cachanado,Arnaud Bourdin,Martine Reynaud-Gaubert,Philippe Bonniaud,Dominique Israel-Biet,Grégoire Prévot,Sandrine Hirschi,François Lebargy,Sylvain Marchand-Adam,Nathalie Bautin,Julie Traclet,Emmanuel Gomez,Sylvie Leroy,Frédéric Gagnadoux,Frédéric Rivière,Emmanuel Bergot,Anne Gondouin,Elodie Blanchard,Antoine Parrot,François-Xavier Blanc,Alexandre Chabrol,Stéphane Dominique,Aude Gibelin,Abdellatif Tazi,Laurence Berard,Pierre Yves Brillet,Marie-Pierre Debray,Alexandra Rousseau,Mallorie Kerjouan,Olivia Freynet,Marie-Christine Dombret,Anne-Sophie Gamez,Ana Nieves,Guillaume Beltramo,Jean Pastré,Aurélie Le Borgne-Krams,Tristan Dégot,C. Launois,Laurent Plantier,Lidwine Wemeau-Stervinou,Jacques Cadranel,Cécile Chenivesse,Dominique Valeyre,Bruno Crestani,Vincent Cottin,Tabassome Simon,Hilario Nunes +50 more
TL;DR: In this paper, a double-blind, placebo-controlled trial was designed to evaluate the efficacy and safety of cyclophosphamide pulses in addition to high-dose methylprednisolone in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF).
Journal ArticleDOI
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
TL;DR: The authors' analysis indicated very frequent aggressive EOL care for patients with lung cancer, regardless of the definition used, and the extent of that aggressiveness and its impact on healthcare costs warrant further studies.
Journal ArticleDOI
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Guillaume Eberst,Amélie Anota,Arnaud Scherpereel,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Hervé Lena,Frédéric Rivière,Isabelle Monnet,Valérie Gounant,H. Janicot,Radj Gervais,C. Locher,Emilie Charton,Franck Morin,Gérard Zalcman,Virginie Westeel +19 more
TL;DR: This study demonstrated that adding bevacizumab to standard chemotherapy in patients with advanced MPM had no negative impact on HRQoL, and a significant improvement in the peripheral neuropathy and pain HRZoL dimensions was even observed.